ImmuScape Completes Series E Financing to Advance Commercialization of Lead CAR-T Therapy IM19 and Next-Generation Cell Therapy Platforms
Imunopharm
Developer of Gene and Cell Therapy Technologies
January 8, 2025Zhongguancun Science City Company Invests in Beijing Yimiaoshenzhou Medical Techology Co., Ltd.("Yimiao Shenzhou" or"Company")Announcement of Official CompletionE-round financing worth hundreds of millions of RMB。This round of financing was led byBeijing-Tianjin-Hebei Coordinated Development Industry Investment FundLeading Investment,Taiping Healthcare Fund, Capital Development Group, Siqi Qing Investment,Sunlight NuoheFollowed by multiple professional institutions.This is the 10th round of strategic financing completed by Beijing Yimiaoshenzhou Medical Techology Co., Ltd. on the occasion of its 10th anniversary, marking a significant milestone and a new starting point as the company advances from clinical research to commercialization in the field of self-developed gene and cell therapies.
The funds from this round of financing will be used to support the commercialization layout of the company's first self-developed CAR-T new drug, IM19, promoting it to become a benchmark product for CAR-T treatment of advanced lymphoma in China after its approval, providing patients with a new treatment option. At the same time, the funds will also accelerate the research and development and clinical progress of new processes and products in major disease areas such as hematological tumors, solid tumors, and autoimmune diseases, helping to build a leading technology platform for next-generation gene and cell drug technologies in China, including rapid CAR-T, universal CAR-T, and gene editing. The construction of an industry-leading large-scale GMP production and manufacturing base will also be advanced, injecting strong momentum into the company’s development.
CEO of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., Dr. He TingExpressed: Deep gratitude to both new and existing shareholders for their recognition and support. This round of financing marks an important milestone in the 10-year development journey of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. We will seize this opportunity to fully advance the commercialization of our first CAR-T product, IM19, as well as the R&D layout of CAR-T treatment products covering major diseases such as hematological tumors, solid tumors, and autoimmune diseases. We will continue to invest in the research and development of next-generation CAR-T processes and technologies, promoting technological iteration and upgrades. Our goal is to ensure that Beijing Yimiaoshenzhou Medical Techology Co., Ltd. maintains a leading position in the global gene and cell drug competition, developing and producing more new and effective drugs with lower costs, better efficacy, and higher safety, benefiting a wide range of patients, supporting industrial development, and serving Healthy China.
Beijing-Tianjin-Hebei Coordinated Development Industry Investment FundStated: As an investment fund focused on the coordinated development of the Beijing-Tianjin-Hebei region, Beijing Yimiaoshenzhou Medical Techology Co., Ltd.'s technological innovation and industrialization capabilities in the field of gene and cell therapy align perfectly with our strategy to support high-tech, high-growth enterprises. We believe that through this collaboration, we will not only accelerate the rapid development of Yimiaoshenzhou but also contribute significantly to the coordinated growth of the cell therapy industry in the Beijing-Tianjin-Hebei region and the rise of China’s cell therapy industry.
Taiping Healthcare FundComment: As an existing shareholder, we are delighted to accompany the long-term growth of Beijing Yimiaoshenzhou Medical Techology Co., Ltd. The Taiping Healthcare Fund has consistently focused on innovative medical technologies in the field of major diseases and will adhere to the investment philosophy of patient capital to help China's innovative drugs benefit more patients. After the commercial launch of Yimiaoshenzhou’s products, the Taiping Healthcare Fund will continue to promote the deep integration of commercial insurance and innovative drugs, contributing Taiping's strength to meet patients' clinical needs.
Beijing First Development Pre-incubation Growth Equity Investment FundStatement: As an investment fund within the Shoufa Group system, we are very pleased to once again participate in the financing of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., and witness the company's growth and progress. This round of financing will provide strong support for Yimiao Shenzhou's research and development and commercialization. We look forward to Yimiao Shenzhou forming a close collaboration with the Global Future Pharmaceutical and Health Industry Incubation Base, constructed by Beijing Shoufa Technology Development Group Science and Technology Service Co., Ltd., achieving more breakthroughs in the field of gene and cell therapy, and bringing more innovative treatment options to patients with serious illnesses such as cancer.
Sijiqing InvestmentIndicates:As a local enterprise, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. has always been one of the key enterprises we focus on and support. We hope to take this round of financing as an opportunity to further optimize the business environment, effectively meet the needs of enterprises, fully serve as the "local steward" for enterprises, help enterprises develop healthily and rapidly, and achieve a win-win situation in social value and economic benefits.
Sunlight NuoheStated: "We are delighted to participate in this round of financing for Beijing Yimiaoshenzhou Medical Techology Co., Ltd. The company's leading position and innovative capabilities in the field of gene and cell therapy drugs have shown us tremendous potential. This round of financing will drive the company’s R&D progress in major disease areas, and we look forward to witnessing the innovation and development of China's innovative drug industry together with Beijing Yimiaoshenzhou."
// About the Beijing-Tianjin-Hebei Industrial Investment Fund //
The Beijing-Tianjin-Hebei Collaborative Development Industrial Investment Fund was established in February 2021 by the People's Governments of Beijing, Tianjin, and Hebei provinces in collaboration with the China Development Bank to thoroughly implement the major national strategy of Beijing-Tianjin-Hebei collaborative development and fully leverage the guiding and amplifying role of fiscal funds from the three regions. The initial scale of the fund is 4.15 billion yuan, with a focus on supporting areas such as regional scientific and technological innovation and high-end manufacturing.
// About Taiping Healthcare Fund //
Taiping Medical and Health Fund is a private equity investment fund managed by Taiping Innovation, a subsidiary of China Taiping Insurance Group, with a registered size of 10 billion yuan. Taiping Group's equity investment business has long focused on the medical and health industry. Under the guidance of the Healthy China strategy, Taiping Innovation closely aligns its investments with Taiping Group’s core insurance business to achieve mutual empowerment between fund investments and the main insurance operations, supporting the creation of China Taiping's "Insurance + Medical Care and Elderly Care" ecosystem. In managing this fund, Taiping Innovation adopts an F+D investment strategy, focusing on sectors including biopharmaceuticals and pharmaceutical outsourcing, medical devices and diagnostics, medical services, biotechnology, and medical informatization, while also covering health technology and health consumption.
// About Shoufa Group //
Beijing Capital Science and Technology Development Group was established in December 2014. It is an important carrier for Beijing to accelerate the reform of the science and technology system, promote the reform of public institutions, and establish a "corporate" technology transfer "pre-incubation" innovation service model. It is committed to building a "pre-incubation" innovation service platform with global influence, promoting the landing of major scientific and technological achievements projects in Beijing that have significant value both domestically and internationally and are still in the application exploration or preliminary research stage.
// About Si Ji Qing Investment //
Sijiqing Investment is an investment company under Sijiqing Town, Haidian District, Beijing. Relying on nearly one million square meters of high-quality park resources within the jurisdiction of Sijiqing Town, it closely follows the overall deployment of the 2024 Haidian District Economic and Social High-Quality Development Conference regarding Haidian District's commitment to "adhering to the leadership of scientific and technological innovation, firmly shouldering the banner of artificial intelligence’s pioneering development, continuously strengthening the pharmaceuticals and health industry, and striving to cultivate more innovative industrial clusters with technological dominance and global competitiveness." The company focuses on industries such as pharmaceuticals and health, cybersecurity, aerospace information, and others. By establishing industrial funds, it drives the transformation of scientific and technological achievements in Haidian District and helps Sijiqing Town rapidly achieve a high-level industrial cluster.
// About Sunshine Nuohé //
Beijing Sunlight Nuohar Pharmaceutical Research Co., Ltd., as a leading Contract Research Organization (CRO) in China's drug development services sector, not only possesses 36,300 square meters of research laboratories and over 80% of its staff dedicated to R&D, but has also established advanced technology platforms across multiple fields such as drug discovery, pharmaceutical research, clinical trials, and bioanalysis. The company maintains robust innovation capabilities, with 12 self-initiated R&D projects in its pipeline for innovative drugs targeting indications like pain relief, kidney disease and dialysis, and cancer supportive care. Several of these projects have no equivalent products currently on the market in China, showcasing the company’s strong R&D momentum and ability to transform research into results. By continuously increasing investment in R&D and technological innovation, the company is able to provide comprehensive one-stop drug development services to China’s pharmaceutical enterprises and research institutions, committed to helping domestic pharmaceutical manufacturers accelerate import substitution and achieve independent innovation.
// About Yimiao Shenzhou //
Yimiao Shenzhou, established in 2015 and headquartered in Beijing, is a leading innovative pharmaceutical company at the commercialization stage. With the mission of "making cancer no longer an incurable disease," it focuses on applying cutting-edge gene and cell drug technologies to treat major diseases such as cancer and autoimmune disorders. To date, the company has completed 10 rounds of strategic financing and owns a one-stop, proprietary gene and cell drug R&D and industrialization platform. It has mastered several core technologies, won the highest award (Outstanding Prize) in the finals of China's Disruptive Technology Innovation Competition, obtained seven clinical trial approvals for Class 1 new drugs, and received Beijing’s first-ever Drug Manufacturing License for gene and cell therapy products. Its R&D pipeline covers hematological cancers such as lymphoma, leukemia, and myeloma, as well as solid tumors including liver cancer, colorectal cancer, and melanoma. Yimiao Shenzhou is a leader in the field of gene and cell therapies.
The company has undertaken more than 10 national and provincial scientific research projects, including the Special Project of the Ministry of Science and Technology's Key R&D Program, the National Health Commission's Science and Technology Innovation - 2030 Major Project, the "Challenge Leader" technical project for cell therapy by the National Innovation Center, and the Beijing Municipal Science and Technology Major Special Project. It has obtained important qualifications such as a National High-tech Enterprise, a Beijing Specialized,精细化, and Innovative Enterprise, a Zhongguancun Frontier Technology Enterprise, a Zhongguancun High-tech Enterprise, and a Postdoctoral Research Workstation. The team has been honored with awards such as Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, Beijing Outstanding Engineer, Haidian District Haiying Talent of Beijing, Xingguomen Leading Talent of Daxing District in Beijing, the Gold Award (First Place) at Tsinghua University President’s Cup Innovation Challenge, MIT's 35 Innovators Under 35, and Fortune Magazine's 40 Under 40 Business Elites.
Source: Beijing Yimiaoshenzhou Medical Techology Co., Ltd.
